These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38990573)

  • 1. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
    Jeong S; Oh YH; Ahn JC; Choi S; Park SJ; Kim HJ; Lee G; Son JS; Jang H; Lee DH; Sha M; Chen L; Kim W; Park SM
    Clin Mol Hepatol; 2024 Jul; 30(3):487-499. PubMed ID: 38711390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC.
    Lee MH; Chen YT; Huang YH; Lu SN; Yang TH; Huang JF; Yin SC; Yeh ML; Huang CF; Dai CY; Chuang WL; Yu ML; Yang HI; Chen HY; Chen CJ
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1275-1285.e2. PubMed ID: 38365094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
    Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
    JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
    Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
    Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiometabolic risk factors in MASLD patients with HCC: the other side of the coin.
    Meroni M; Longo M; Dongiovanni P
    Front Endocrinol (Lausanne); 2024; 15():1411706. PubMed ID: 38846491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease.
    Lee HW; Kim KH; Ahn SH; Lee HC; Choi J
    Liver Int; 2024 Jun; 44(6):1448-1455. PubMed ID: 38488679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Vaz J; Jepsen P; Strömberg U; Midlöv P; Eriksson B; Buchebner D; Hagström H
    Int J Cancer; 2024 Jul; ():. PubMed ID: 39016032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring occupational toxicant exposures in patients with metabolic dysfunction-associated steatotic liver disease: A prospective pilot study.
    Tovoli F; Stefanini B; Mandrioli D; Mattioli S; Vornoli A; Sgargi D; Manservisi F; Piscaglia F; Curti S; Bolondi L
    Dig Liver Dis; 2024 Apr; 56(4):571-578. PubMed ID: 38151451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
    Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W
    Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
    Xiao S; Liu Y; Fu X; Chen T; Xie W
    Am J Med; 2024 Jul; ():. PubMed ID: 39047929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Sarkar S; Alurwar A; Ly C; Piao C; Donde R; Wang CJ; Meyers FJ
    Gastro Hep Adv; 2024; 3(4):498-505. PubMed ID: 39131709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to Agent Orange and Hepatocellular Carcinoma Among US Military Personnel.
    Benhammou JN; Leng M; Shah SC; Cholankeril G; Dong TS; Patel AA; Tong MJ
    JAMA Netw Open; 2023 Dec; 6(12):e2346380. PubMed ID: 38048128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between serum ferritin baselines and trajectories and the incidence of metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.
    Song Z; Miao X; Xie X; Tang G; Deng J; Hu M; Liu S; Leng S
    Lipids Health Dis; 2024 May; 23(1):141. PubMed ID: 38760825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.
    Simon TG; Wilechansky RM; Stoyanova S; Grossman A; Dichtel LE; Lauer GM; Miller KK; Hoshida Y; Corey KE; Loomba R; Chung RT; Chan AT
    JAMA; 2024 Mar; 331(11):920-929. PubMed ID: 38502074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.